# CTOR catalysts: CITIUS ONCOLOGY, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ctor/catalysts

> CITIUS ONCOLOGY, INC. (CTOR) has no upcoming catalysts in this calendar. The latest recorded is the CITIUS ONCOLOGY, INC. earnings report, August 14, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | CITIUS ONCOLOGY, INC. |
| Ticker | CTOR (Nasdaq) |
| SEC CIK | 1851484 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/ctor |

## Cash runway

Cash $16.6M as of 2026-06-30; quarterly burn $2.7M; about 18.3 months of runway at that rate (XBRL company facts, accession 0001213900-26-090184).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 27, 2022 | [CITIUS ONCOLOGY, INC. NDA/BLA acceptance](https://sec-api.dev/companies/ctor/catalysts) | CTOR |  | completed | "The BLA was filed with the FDA on September 27, 2022, refiled on February 13, 2024, and accepted by the FDA on March 18, 2024 and we received a BLA approval on August 8, 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1851484/000121390025014320/ea0230776-10q_citius.htm)) |
| July 28, 2023 | [LYMPHIR (lymphir) PDUFA date](https://sec-api.dev/pdufa/lymphir) | CTOR |  | completed, complete response letter | "In December 2022, a Biologics License Application ("BLA") for LYMPHIR was accepted for filing with the FDA and a PDUFA goal date was set for July 28, 2023." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1851484/000121390024113150/ea0225372-10k_citius.htm)) |
| July 29, 2023 | [LYMPHIR (lymphir) complete response letter (CRL)](https://sec-api.dev/pdufa/lymphir) | CTOR |  | completed, complete response letter | "On July 29, 2023, we received a Complete Response Letter, ("CRL") from the FDA regarding the BLA seeking approval for LYMPHIR." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1851484/000121390024113150/ea0225372-10k_citius.htm)) |
| Sep 2023 | [LYMPHIR (lymphir) complete response letter (CRL)](https://sec-api.dev/pdufa/lymphir) | CTOR |  | completed, complete response letter | "In September 2023, we announced that the FDA had agreed with our plans to address the requirements outlined in the CRL, which guidance provided us with a path for completing the necessary activities to support the resubmission of the BLA for LYMPHIR and we received approval from the FDA in August 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1851484/000121390025125331/ea0270097-10k_citius.htm)) |
| Aug 2024 | [Denileukin FDA approval](https://sec-api.dev/pdufa/denileukin) | CTOR |  | completed, approved | "LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA in August 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1851484/000121390025116764/ea026756001ex99-2_citius.htm)) |
| Aug 2024 | [LYMPHIR (lymphir) FDA approval](https://sec-api.dev/pdufa/lymphir) | CTOR | with relapsed or refractory CTCL | completed, approved | "LYMPHIR was approved by the FDA in August 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1851484/000121390025010748/ea023015701ex99-1_citius.htm)) |
| August 13, 2024 | [LYMPHIR (lymphir) PDUFA date](https://sec-api.dev/pdufa/lymphir) | CTOR |  | scheduled | "The FDA assigned a PDUFA goal date of August 13, 2024 and approved LYMPHIR on August 8, 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1851484/000121390025125331/ea0270097-10k_citius.htm)) |
| November 11, 2024 | [KEYTRUDA® (pembrolizumab) trial start](https://sec-api.dev/pdufa/pembrolizumab) | CTOR | recurrent solid tumors | completed | "On November 11, 2024, Citius Oncology, Inc. issued a press release to announce preliminary results from an ongoing investigator-initiated Phase I clinical trial evaluating the safety and efficacy of a combined regimen of pembrolizumab and LYMPHIR™ (denileukin diftitox-cxdl or E7777) in patients with recurrent solid tumors." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1851484/000121390024096269/ea0220666-8k_citius.htm)) |
| December 27, 2024 | [CITIUS ONCOLOGY, INC. earnings report](https://sec-api.dev/companies/ctor/catalysts) | CTOR |  | completed | "Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1851484/000121390024113159/ea022616501ex99-1_citius.htm)) |
| May 14, 2025 | [CITIUS ONCOLOGY, INC. earnings report](https://sec-api.dev/companies/ctor/catalysts) | CTOR |  | completed | "Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal second quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1851484/000121390025043363/ea024197201ex99-1_citius.htm)) |
| August 12, 2025 | [CITIUS ONCOLOGY, INC. earnings report](https://sec-api.dev/companies/ctor/catalysts) | CTOR |  | completed | "Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal third quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1851484/000121390025075014/ea025288401ex99-1_citius.htm)) |
| Dec 2025 | [LYMPHIR (lymphir) FDA approval](https://sec-api.dev/pdufa/lymphir) | CTOR |  | completed, approved | "LYMPHIR was approved by the FDA and subsequently launched in the U.S. in December 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1851484/000121390026115964/ea031092801ex99-1.htm)) |
| Dec 2025 | [Denileukin FDA approval](https://sec-api.dev/pdufa/denileukin) | CTOR |  | completed, approved | "LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA and subsequently launched in the U.S. in December 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1851484/000121390026063530/ea029290301ex99-1.htm)) |
| December 23, 2025 | [KEYTRUDA® (pembrolizumab) trial start](https://sec-api.dev/pdufa/pembrolizumab) | CTOR |  | completed | "Announced promising preliminary results of an investigator-initiated Phase I clinical trial of pembrolizumab and LYMPHIR™ in cancer patients with recurrent solid tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1851484/000121390025125418/ea027077501ex99-1_citius.htm)) |
| December 23, 2025 | [CITIUS ONCOLOGY, INC. earnings report](https://sec-api.dev/companies/ctor/catalysts) | CTOR |  | completed | "("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal year ended September 30, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1851484/000121390025125418/ea027077501ex99-1_citius.htm)) |
| February 13, 2026 | [CITIUS ONCOLOGY, INC. earnings report](https://sec-api.dev/companies/ctor/catalysts) | CTOR |  | completed | "("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the fiscal first quarter ended December 31, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1851484/000121390026015894/ea027694701ex99-1_citius.htm)) |
| March 4, 2026 | [Denileukin topline data readout](https://sec-api.dev/pdufa/denileukin) | CTOR | high risk relapsed or refractory diffuse large B cell lymphoma | completed, positive | "On March 4, 2026, we issued a press release announced positive topline safety and efficacy results from an investigator initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox cxdl) administered prior to commercial CD19 directed CAR T therapy in patients with high risk relapsed or refractory diffuse large B cell lymphoma (DLBCL)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1851484/000121390026023440/ea0277423-8k_citius.htm)) |
| March 4, 2026 | [LYMPHIR (lymphir) topline data readout](https://sec-api.dev/pdufa/lymphir) | CTOR | high risk relapsed or refractory diffuse large B cell lymphoma | completed, positive | "On March 4, 2026, we announced positive topline safety and efficacy results from an investigator-initiated Phase 1 trial evaluating LYMPHIR administered prior to commercial CD19 directed" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1851484/000121390026090184/ea0301678-10q_citius.htm)) |
| March 4, 2026 | [Denileukin trial start](https://sec-api.dev/pdufa/denileukin) | CTOR | high risk relapsed or refractory diffuse large B cell lymphoma | completed | "On March 4, 2026, we issued a press release announced positive topline safety and efficacy results from an investigator initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox cxdl) administered prior to commercial CD19 directed CAR T therapy in patients with high risk relapsed or refractory diffuse large B cell lymphoma (DLBCL)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1851484/000121390026023440/ea0277423-8k_citius.htm)) |
| March 10, 2026 | [LYMPHIR (lymphir) trial start](https://sec-api.dev/pdufa/lymphir) | CTOR |  | completed | "On March 10, 2026, we issued a press release announcing positive topline results from a completed investigator-initiated Phase 1 clinical trial conducted by University of Pittsburgh investigators." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1851484/000121390026025464/ea0280663-8k_citius.htm)) |
| March 10, 2026 | [CITIUS ONCOLOGY, INC. topline data readout](https://sec-api.dev/companies/ctor/catalysts) | CTOR |  | completed, positive | "On March 10, 2026, we announced positive topline results from a completed investigator-initiated Phase 1 clinical trial conducted by University of Pittsburgh investigators." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1851484/000121390026090184/ea0301678-10q_citius.htm)) |
| May 15, 2026 | [LYMPHIR (lymphir) trial start](https://sec-api.dev/pdufa/lymphir) | CTOR |  | completed | "Announced positive topline results from two investigator-initiated Phase 1 studies evaluating LYMPHIR in combination settings, including:" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm)) |
| May 15, 2026 | [CITIUS ONCOLOGY, INC. earnings report](https://sec-api.dev/companies/ctor/catalysts) | CTOR |  | completed | "Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea029103501ex99-1.htm)) |
| August 14, 2026 | [CITIUS ONCOLOGY, INC. earnings report](https://sec-api.dev/companies/ctor/catalysts) | CTOR |  | completed | "Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1851484/000121390026090182/ea030222601ex99-1.htm)) |

## Drugs

- [Denileukin](https://sec-api.dev/pdufa/denileukin): high risk relapsed or refractory diffuse large b cell lymphoma, high-risk relapsed or refractory diffuse large b-cell lymphoma
- [LYMPHIR (lymphir)](https://sec-api.dev/pdufa/lymphir): cutaneous t-cell lymphoma, with relapsed or refractory ctcl, with relapsed or refractory stage i-iii ctcl, high risk relapsed or refractory diffuse large b cell lymphoma, with relapsed or refractory stage

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ctor/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CTOR catalysts: CITIUS ONCOLOGY, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ctor/catalysts

```bibtex
@misc{secapidev_companies_ctor_catalysts_20261116,
  title        = {CTOR catalysts: CITIUS ONCOLOGY, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ctor/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ctor_catalysts_20261116","title":"CTOR catalysts: CITIUS ONCOLOGY, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ctor/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
